“revenue dollars for the remainder of the year they're expected to be fairly linear with Q4 being slightly higher than Q2 and Q3.”

In context

“1.8% and $0.54 on adjusted EPS. We continue to expect net interest expense of approximately $490 million for the year. We now expect an adjusted income tax rate of 13.1% in 2022, slightly higher than the prior guide driven by the improved earnings outlook. We continue to assume net capital expenditures of approximately $2.5 billion to $2.7 billion and free cash flow of approximately $7 billion. A guidance still assumes $2.5 billion of capital deployment, which is the $2 billion of share buybacks that we completed in January and $475 million of capital to return to shareholders through dividends. And we now estimate that the full year average diluted share count will be between 394 million and 395 million shares. And finally, a couple of comments on phasing to help you with your modeling, revenue dollars for the remainder of the year they're expected to be fairly linear with Q4 being slightly higher than Q2 and Q3. Core organic growth for Q2 is expected to be lower than Q3 and Q4 due to an estimated 200 basis point impact of lockdowns in China. And in terms of adjusted EPS phasing, we expect Q2 as a percentage of the full year to be just slightly lower than the comparable periods last year. To conclude we'd live an excellent start to the year, and we're in a great position to achieve our 2022 goals. With that, I'll turn the call back over to Raf. Rafael Tejada: Thank you, Stephen. Operator, we're ready to take questions. Operator: Thank you. [Operator Instructions] And our first question today comes from Jack Meehan of Nephron Research. Jack, please go ahead. Your line is open. Jack Meehan: Thank you. Good morning. Hope you guys are doing well. My question – are on the Biopharma side. First question”